Actionable news
0
All posts from Actionable news
Actionable news in ALXN: Alexion Pharmaceuticals, Inc.,

Alexion Pharmaceuticals (ALXN) Stock Gets ‘Outperform’ Rating at RBC Capital

NEW YORK (TheStreet) -- Shares of Alexion Pharmaceuticals (ALXN) are down by 1.47% to $123.51 in mid-afternoon trading on Wednesday, as the stock was initiated with an "outperform" rating at RBC Captial earlier today. The firm has a $188 price target on the stock.

The coverage comes as the firm expects Alexion "to continue to dominate the rare disease space."

The Cheshire, CT-based pharmaceutical company entered the rare disease sector in 2007 with Soliris in PNH (paroxysmal nocturnal hemoglobinuria), added aHUS (atypical hemolytic uremic syndrome) in 2014, and reported $2.6 billion in worldwide sales last year, according to the analyst note.

"Alexion's rare disease foothold expanded with Soliris' second...


More